Session

IBD (Posters)

TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS
TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS

IBD (Posters)  et al.

COMPARISON OF TWO ANALYTICAL TECHNIQUES FOR QUANTIFYING INFLIXIMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF TWO ANALYTICAL TECHNIQUES FOR QUANTIFYING INFLIXIMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER
ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER

IBD (Posters)  et al.

EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER
EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER

IBD (Posters)  et al.

DECREASED MUSCLE MASS AND STRENGTH IN INFLAMMATORY BOWEL DISEASE PATIENTS
DECREASED MUSCLE MASS AND STRENGTH IN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

IBD (Posters)  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

IBD (Posters)  et al.

RETROSPECTIVE ONE-CENTER STUDY COMPARING SAFETY AND EFFICACY OF IRON FORMULATIONS (FERRIC DERISOMALTOSE AND CARBOXYMALTOSE) IN GASTROENTEROLOGICAL PATIENTS
RETROSPECTIVE ONE-CENTER STUDY COMPARING SAFETY AND EFFICACY OF IRON FORMULATIONS (FERRIC DERISOMALTOSE AND CARBOXYMALTOSE) IN GASTROENTEROLOGICAL PATIENTS

IBD (Posters)  et al.

MEDICAL CANNABIS REDUCES PAIN AND IMPROVES SLEEP QUALITY IN CROHN'S DISEASE PATIENTS. A PROSPECTIVE OBSERVATIONAL STUDY
MEDICAL CANNABIS REDUCES PAIN AND IMPROVES SLEEP QUALITY IN CROHN'S DISEASE PATIENTS. A PROSPECTIVE OBSERVATIONAL STUDY

IBD (Posters)  et al.

COMPARATIVE FREQUENCY OF STRUCTURAL CHANGES IN THE PANCREAS IN CHRONIC PANCREATITIS AND INFLAMMATORY BOWEL DISEASES BY ENDOSONOGRAPHY
COMPARATIVE FREQUENCY OF STRUCTURAL CHANGES IN THE PANCREAS IN CHRONIC PANCREATITIS AND INFLAMMATORY BOWEL DISEASES BY ENDOSONOGRAPHY

IBD (Posters)  et al.

ADAPTATION OF QUESTIONNAIRES USED IN THE TRANS-IBD RANDOMISED CLINICAL TRIAL
ADAPTATION OF QUESTIONNAIRES USED IN THE TRANS-IBD RANDOMISED CLINICAL TRIAL

IBD (Posters)  et al.

FACTORS INFLUENCING INFLIXIMAB FAILURE IN ANTI-TNF NAIVE CHILDREN WITH ACTIVE ULCERATIVE COLITIS
FACTORS INFLUENCING INFLIXIMAB FAILURE IN ANTI-TNF NAIVE CHILDREN WITH ACTIVE ULCERATIVE COLITIS

IBD (Posters)  et al.

GENOMIC DIVERSITY OF FAECALIBACTERIUM PRAUSNITZII STRAINS FROM MICROBIOTA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY VOLUNTEERS
GENOMIC DIVERSITY OF FAECALIBACTERIUM PRAUSNITZII STRAINS FROM MICROBIOTA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY VOLUNTEERS

IBD (Posters)  et al.

PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE
PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE
EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE

IBD (Posters)  et al.

NEED FOR VEDOLIZUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE
NEED FOR VEDOLIZUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE

IBD (Posters)  et al.

A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY
A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY

IBD (Posters)  et al.

THE USE OF NUTRITION AS A THERAPEUTIC STRATEGY IN CHILDREN AND ADOLESCENTS WITH CROHN’S DISEASE IN BELGIUM
THE USE OF NUTRITION AS A THERAPEUTIC STRATEGY IN CHILDREN AND ADOLESCENTS WITH CROHN’S DISEASE IN BELGIUM

IBD (Posters)  et al.

PARTICULATE MATTER FROM NATURAL PRECURSOR INCREASES SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE
PARTICULATE MATTER FROM NATURAL PRECURSOR INCREASES SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

PREDICTIVE FACTORS OF MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWELDISEASES
PREDICTIVE FACTORS OF MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWELDISEASES

IBD (Posters)  et al.

Item 581 - 600 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
30
31